Correlation Between Alar Pharmaceuticals and Synmosa Biopharma

Can any of the company-specific risk be diversified away by investing in both Alar Pharmaceuticals and Synmosa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alar Pharmaceuticals and Synmosa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Alar Pharmaceuticals and Synmosa Biopharma, you can compare the effects of market volatilities on Alar Pharmaceuticals and Synmosa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alar Pharmaceuticals with a short position of Synmosa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alar Pharmaceuticals and Synmosa Biopharma.

Diversification Opportunities for Alar Pharmaceuticals and Synmosa Biopharma

0.87

Correlation Coefficient

Alar Pharmaceuticals  Synmosa Biopharma

Very poor diversification

The 3 months correlation between Alar and Synmosa is 0.87. Overlapping area represents the amount of risk that can be diversified away by holding Alar Pharmaceuticals and Synmosa Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Synmosa Biopharma and Alar Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alar Pharmaceuticals are associated (or correlated) with Synmosa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Synmosa Biopharma has no effect on the direction of Alar Pharmaceuticals i.e., Alar Pharmaceuticals and Synmosa Biopharma go up and down completely randomly.

Pair Corralation between Alar Pharmaceuticals and Synmosa Biopharma

Assuming the 90 days trading horizon Alar Pharmaceuticals is expected to under-perform the Synmosa Biopharma. In addition to that, Alar Pharmaceuticals is 3.69 times more volatile than Synmosa Biopharma. It trades about -0.12 of its total potential returns per unit of risk. Synmosa Biopharma is currently generating about -0.21 per unit of volatility. If you would invest  3,795  in Synmosa Biopharma on September 3, 2024 and sell it today you would lose (365.00) from holding Synmosa Biopharma or give up 9.62% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Alar Pharmaceuticals  vs.  Synmosa Biopharma

Alar Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Alar Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Synmosa Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Synmosa Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Pair Trading with Alar Pharmaceuticals and Synmosa Biopharma

The main advantage of trading using opposite Alar Pharmaceuticals and Synmosa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alar Pharmaceuticals position performs unexpectedly, Synmosa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Synmosa Biopharma will offset losses from the drop in Synmosa Biopharma's long position.

The idea behind Alar Pharmaceuticals and Synmosa Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.